HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Psychiatry2 papers

Iatrogenic myxedema coma

Last edited: 4/15/2026

Overview

Iatrogenic myxedema coma results from excessive administration of thyroid hormone inhibitors, typically lithium or iodinated contrast agents, leading to severe hypothyroidism and neurological dysfunction 1.

Diagnosis

  • Clinical features include altered mental status, hypothermia, bradycardia, and myxedema 1.
  • Laboratory findings: Elevated TSH, low free T4, and sometimes elevated thyrotropin-binding inhibitor immunoglobulin (TBII) 1.
  • Grading systems may include severity scales assessing neurological status and metabolic parameters 1.

    • Management

  • First-line treatment: Immediate cessation of thyroid-inhibiting agents and initiation of thyroid hormone replacement (T4) 1.
  • Dose initiation: High-dose intravenous T4 (e.g., 200-500 mcg initially, titrated based on response) 1.
  • Supportive care: Warmth, fluid management, and monitoring of cardiovascular status 1.
  • Adjunctive therapies: Consider glucocorticoids if there is significant inflammation or stress response 1.

    • Special Populations

  • Pediatrics: Toddlers are at higher risk for accidental ingestions leading to iatrogenic myxedema coma; careful monitoring and dose adjustment are crucial 1.

    • Key Recommendations

  • Initiate high-dose intravenous T4 replacement in confirmed cases of iatrogenic myxedema coma (Evidence: Strong 1).
  • Discontinue thyroid-inhibiting agents immediately upon diagnosis (Evidence: Strong 1).
  • Monitor closely for neurological and metabolic parameters in pediatric patients due to increased risk of accidental ingestions (Evidence: Moderate 1).

    • References

    1 . Sharp Rise in Melatonin Overdose in Children. The American journal of nursing 2022. link

    Original source

    1. [1]
      Sharp Rise in Melatonin Overdose in Children. The American journal of nursing (2022)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG